Crescent Biopharma, Inc. (NASDAQ: CBIO) is a Healthcare company (Biotechnology) with a market capitalization of $507M. The Maz Rating grades it against the other companies in its sector.
Crescent Biopharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.04, Crescent Biopharma, Inc. trades at 33.9x sales and 1.9x book value. Over the last twelve months it generated about $15M of revenue and a net loss of $274M. It runs a gross margin of 99.6%, an operating margin of -1216.6% and a net margin of -1174.0%. It shows return on equity of -85.4%, return on invested capital of -65.9% and a free cash flow yield of -31.6%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 12.57. Over the past 52 weeks the share price ranged from $8.72 to $27.41, with a beta of 1.39.
Crescent Biopharma, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 10 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.